Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US.
Pankit VachhaniEvelyn M FlahavanTao XuEsprit MaMelissa MontezAnda GershonMaika OnishiHuan JinGrace KuBrannon FloresCat N BuiJonathan A AbbasWilliam DonnellanPublished in: The oncologist (2022)
This study reflects early real-world experience with venetoclax + HMAs in a predominantly community setting and emphasizes the importance of appropriate venetoclax management in optimizing patient outcomes.